SIRs for cancer in people with PID in Australia
| Cancer site . | ICD-10/ICDO-3 codes* . | O . | E . | SIR (95% CI) . |
|---|---|---|---|---|
| Lip | C00 | 0 | 0.51 | 0-7.26† |
| Oral cavity, oropharynx | C01, C02, C03-C06, C09, C10 | 0 | 0.44 | 0-8.33† |
| Stomach | C16 | 3 | 0.49 | 6.10 (1.26-17.8)‡ |
| Colon | C18 | 4 | 2.99 | 1.34 (0.36-3.43) |
| Anus | C21 | 0 | 0.10 | 0-38.0† |
| Pancreas | C25 | 1 | 0.39 | 2.55 (0.06-14.2) |
| Trachea, bronchus, lung | C33-C34 | 2 | 1.97 | 1.02 (0.12-3.67) |
| Thymus gland | C37 | 2 | 0.03 | 67.3 (8.15-243)‡ |
| Melanoma | C43 | 4 | 4.95 | 0.81 (0.22-2.07) |
| Breast (females only) | C50 | 12 | 7.66 | 1.57 (0.81-2.74) |
| Vulva, vagina, cervix uteri | C51-C53 | 0 | 0.79 | 0-4.67† |
| Ovary | C56 | 1 | 0.57 | 1.74 (0.04-9.70) |
| Penis | C60 | 0 | 0.02 | 0-167† |
| Prostate | C61 | 3 | 3.42 | 0.88 (0.18-2.57) |
| Bladder | C67 | 3 | 0.75 | 3.99 (0.82-11.7) |
| Brain | C71 | 0 | 0.46 | 0-8.02† |
| Thyroid gland | C73 | 1 | 0.75 | 1.34 (0.03-7.45) |
| Adrenal gland | C74 | 1 | 0.04 | 26.3 (0.67-147) |
| Hodgkin lymphoma | ICDO-3 9650-9677 | 1 | 0.29 | 3.47 (0.09-19.4) |
| Non-Hodgkin lymphoma§ | ICDO-3 9591, 9596, 9670-9729, 9761, 9820-9837, 9940, 9948 and 9590 if ICD-10, C82-C85 | 16 | 1.81 | 8.82 (5.04-14.3)‡ |
| Leukemia‖ | ICDO-3 9800-9989, excluding 9820-9837, 9940, 9948 | 4 | 0.75 | 5.36 (1.46-13.7)‡ |
| All malignant neoplasms | C00-C96, excluding C44 | 58 | 36.2 | 1.60 (1.22-2.07)‡ |
| Cancer site . | ICD-10/ICDO-3 codes* . | O . | E . | SIR (95% CI) . |
|---|---|---|---|---|
| Lip | C00 | 0 | 0.51 | 0-7.26† |
| Oral cavity, oropharynx | C01, C02, C03-C06, C09, C10 | 0 | 0.44 | 0-8.33† |
| Stomach | C16 | 3 | 0.49 | 6.10 (1.26-17.8)‡ |
| Colon | C18 | 4 | 2.99 | 1.34 (0.36-3.43) |
| Anus | C21 | 0 | 0.10 | 0-38.0† |
| Pancreas | C25 | 1 | 0.39 | 2.55 (0.06-14.2) |
| Trachea, bronchus, lung | C33-C34 | 2 | 1.97 | 1.02 (0.12-3.67) |
| Thymus gland | C37 | 2 | 0.03 | 67.3 (8.15-243)‡ |
| Melanoma | C43 | 4 | 4.95 | 0.81 (0.22-2.07) |
| Breast (females only) | C50 | 12 | 7.66 | 1.57 (0.81-2.74) |
| Vulva, vagina, cervix uteri | C51-C53 | 0 | 0.79 | 0-4.67† |
| Ovary | C56 | 1 | 0.57 | 1.74 (0.04-9.70) |
| Penis | C60 | 0 | 0.02 | 0-167† |
| Prostate | C61 | 3 | 3.42 | 0.88 (0.18-2.57) |
| Bladder | C67 | 3 | 0.75 | 3.99 (0.82-11.7) |
| Brain | C71 | 0 | 0.46 | 0-8.02† |
| Thyroid gland | C73 | 1 | 0.75 | 1.34 (0.03-7.45) |
| Adrenal gland | C74 | 1 | 0.04 | 26.3 (0.67-147) |
| Hodgkin lymphoma | ICDO-3 9650-9677 | 1 | 0.29 | 3.47 (0.09-19.4) |
| Non-Hodgkin lymphoma§ | ICDO-3 9591, 9596, 9670-9729, 9761, 9820-9837, 9940, 9948 and 9590 if ICD-10, C82-C85 | 16 | 1.81 | 8.82 (5.04-14.3)‡ |
| Leukemia‖ | ICDO-3 9800-9989, excluding 9820-9837, 9940, 9948 | 4 | 0.75 | 5.36 (1.46-13.7)‡ |
| All malignant neoplasms | C00-C96, excluding C44 | 58 | 36.2 | 1.60 (1.22-2.07)‡ |
95% CI indicates 95% confidence interval; E, expected number of cases; ICD, International Classification of Diseases; ICDO, International Classification of Diseases for Oncology; NHL, non-Hodgkin lymphoma; O, observed number of cases; PID, primary immune deficiency; and SIR, standardized incidence ratio.
Lymphoid and hematopoietic neoplasms were classified according to current guidelines for epidemiologic studies23 and include 2 cases with ICDO-3 9960 morphology and ICD-10 D47 topography.
One-tail, 97.5% CI instead of 95% CI because of zero observations.
Statistical significance.
Diffuse large B-cell lymphoma (n = 1), follicular lymphoma (n = 3), Burkitt lymphoma/leukemia (n = 1), small lymphocytic lymphoma (n = 1), extranodal marginal zone lymphoma type (n = 1; body site location not specified in national cancer registry records), peripheral T-cell lymphoma (n = 1) unclassified, cutaneous T-cell lymphoma unclassified (n = 1), Waldenström macroglobulinemia (n = 1), NHL unclassified (n = 6).
Chronic myeloproliferative leukemia (n = 2), acute myeloid leukemia (n = 1), and myeloid neoplasms unclassified (n = 1).